Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Neoplasms 1Endometrial Neoplasms 1Carcinoma 1

Interventions

Paclitaxel 4pembrolizumab 3Cisplatin 3Doxorubicin 2Carboplatin 2Brachytherapy 2Biopsy 2trastuzumab deruxtecan 1sacituzumab govitecan 1relugolix 1dostarlimab 1dehydroftorafur 1belzutifan 1Watchful Waiting 1Vaginal Smears 1VMBP protocol 1Ultrasound, High-Intensity Focused, Transrectal 1Transurethral Resection of Prostate 1Taxes 1Sutures 1Standard of Care 1Radiotherapy, Intensity-Modulated 1Pregnancy Tests 1Practice Guidelines as Topic 1Platinum 1Papanicolaou Test 1Oxaliplatin 1Mitozytrex 1Mitomycin 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Uterine Neoplasms × VMBP protocol × Clear all
NCT05559879 2026-04-15

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

University of Alabama at Birmingham

Phase 1/2 Recruiting
37 enrolled
Gynecologic

Carcinoma, Uterine Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡